Micromet, Inc.
Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company’s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin’s lymphoma (NHL). A second BiTE antibody, MT110, is being tested in a phase I clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule (EpCAM), which is over-expressed in many solid tumors.
Contact Details
Office Address
Micromet, Inc.
6707 Democracy Blvd., Suite 505
Bethesda, MD, USA 20817
Phone: (240) 752-1420
Fax: (240) 752-1425
Executives
Chief Exec. Officer
Dr. Christian Itin
Chief Financial Officer
Mr. Barclay A. Phillips